Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Sets New 1-Year Low – Here’s Why

Shares of Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $52.25 and last traded at $52.25, with a volume of 0 shares changing hands. The stock had previously closed at $52.25.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on RCDTF shares. Royal Bank of Canada raised shares of Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research note on Monday, October 7th. Barclays raised shares of Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a research report on Tuesday, October 22nd.

Recordati Industria Chimica e Farmaceutica Price Performance

The stock has a market cap of $10.78 billion, a P/E ratio of 26.13 and a beta of 0.33. The firm has a 50 day moving average price of $52.25 and a 200 day moving average price of $51.94. The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.73.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.